We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Patient, physician, and policy factors underlying variation in use of telemedicine for radiation oncology cancer care.
- Authors
De, Brian; Fu, Shuangshuang; Chen, Ying‐Shiuan; Das, Prajnan; Ku, Kimberly; Maroongroge, Sean; Woodhouse, Kristina D.; Hoffman, Karen E.; Nguyen, Quynh‐Nhu; Reed, Valerie K.; Chen, Aileen B.; Koong, Albert C.; Smith, Benjamin D.; Smith, Grace L.
- Abstract
Background: Oncology telemedicine was implemented rapidly after COVID‐19. We examined multilevel correlates and outcomes of telemedicine use for patients undergoing radiotherapy (RT) for cancer. Methods: Upon implementation of a telemedicine platform at a comprehensive cancer center, we analyzed 468 consecutive patient RT courses from March 16, 2020 to June 1, 2020. Patients were categorized as using telemedicine during ≥1 weekly oncologist visits versus in‐person oncologist management only. Temporal trends were evaluated with Cochran‐Armitage tests; chi‐squared test and multilevel multivariable logistic models identified correlates of use and outcomes. Results: Overall, 33% used telemedicine versus 67% in‐person only oncologist management. Temporal trends (ptrend < 0.001) correlated with policy changes: uptake was rapid after local social‐distancing restrictions, reaching peak use (35% of visits) within 4 weeks of implementation. Use declined to 15% after national "Opening Up America Again" guidelines. In the multilevel model, patients more likely to use telemedicine were White non‐Hispanic versus Black or Hispanic (odds ratio [OR] = 2.20, 95% confidence interval [CI] 1.03–4.72; p = 0.04) or receiving ≥6 fractions of RT versus 1–5 fractions (OR = 4.49, 95% CI 2.29–8.80; p < 0.001). Model intraclass correlation coefficient demonstrated 43% utilization variation was physician‐level driven. Treatment toxicities and 30‐day emergency visits or unplanned hospitalizations did not differ for patients using versus not using telemedicine (p > 0.05, all comparisons). Conclusion: Though toxicities were similar with telemedicine oncology management, there remained lower uptake among non‐White patients. Continuing strategies for oncology telemedicine implementation should address multilevel patient, physician, and policy factors to optimize telemedicine's potential to surmount—and not exacerbate—barriers to quality cancer care.
- Subjects
ONCOLOGISTS; CANCER treatment; TELEMEDICINE; PHYSICIANS; INTRACLASS correlation; CHI-squared test
- Publication
Cancer Medicine, 2022, Vol 11, Issue 10, p2096
- ISSN
2045-7634
- Publication type
Article
- DOI
10.1002/cam4.4555